Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11851/3997
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKızıltoprak, Hasan-
dc.contributor.authorKoç, Mustafa-
dc.contributor.authorYetkin, Esat-
dc.contributor.authorTekin, Kemal-
dc.contributor.authorİnanç, Merve-
dc.contributor.authorÖzülken, Kemal-
dc.date.accessioned2021-01-22T06:25:58Z-
dc.date.available2021-01-22T06:25:58Z-
dc.date.issued2020-08
dc.identifier.citationKiziltoprak, H., Koc, M., Yetkin, E., Tekin, K., Inanc, M., & Ozulken, K. (2020). Additive Effect of Topical Nepafenac on Mydriasis in Patients With Diabetes Mellitus. Eye & contact lens, 46(5), 310-313.en_US
dc.identifier.issn1542-233X
dc.identifier.urihttps://hdl.handle.net/20.500.11851/3997-
dc.identifier.urihttps://doi.org/10.1097/ICL.0000000000000657-
dc.description.abstractOBJECTIVES: To evaluate the additive effect of topical nepafenac on pupil diameter (PD) in patients with diabetes mellitus (DM) and cataract. METHODS: This prospective comparative study included the patients having cataract surgery with and without DM. Two consecutive PD measurements were taken using an automatic quantitative pupillometry system (MonPack One, Metrovision). A baseline measurement was taken, then one drop of nepafenac % 0.1 (Nevanac; Alcon, Fort Worth, TX) was instilled only to the eye that will be operated on (study eye). Cyclopentolate 1.0% (Sikloplejin; Abdi İbrahim, İstanbul, Turkey) was instilled to both eyes (study eye/fellow eye) 5 minutes later. The second measurement was taken at 1 hour after this application. RESULTS: The DM group consisted of 43 patients, and the control group consisted of 39 participants. The baseline PDs of both eyes were similar in the DM group (P=0.070) and the control group (P=0.345). The change in pupil size from baseline to mydriasis was statistically significantly greater in the study eyes (2.69±0.53) than fellow eyes (2.54±0.61) in the DM group (P=0.009), but there was no statistically significant difference in the control group (2.94±0.63 vs. 2.86±0.58). When the groups were compared, the PD changes were similar in the study eyes between groups (P=0.065), while the PD changes in the fellow eyes were lower in the DM group (P=0.017). CONCLUSIONS: Nepafenac has been shown additive effect on pupil dilation in diabetic patients before cataract surgery.en_US
dc.language.isoenen_US
dc.publisherEye and Contact Lens Association (ECLA)en_US
dc.relation.ispartofEye & contact lensen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCataract surgeryen_US
dc.subjectDiabetes mellitusen_US
dc.subjectNepafenacen_US
dc.subjectPupil dilationen_US
dc.titleAdditive Effect of Topical Nepafenac on Mydriasis in Patients With Diabetes Mellitusen_US
dc.typeArticleen_US
dc.departmentFaculties, School of Medicine, Department of Surgical Sciencesen_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümütr_TR
dc.identifier.volume46
dc.identifier.issue5
dc.identifier.startpage310
dc.identifier.endpage313
dc.authorid0000-0003-2604-2981-
dc.identifier.wosWOS:000571132100014en_US
dc.identifier.scopus2-s2.0-85090068488en_US
dc.institutionauthorÖzülken, Kemal-
dc.identifier.pmid31503086en_US
dc.identifier.doi10.1097/ICL.0000000000000657-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ2-
item.openairetypeArticle-
item.languageiso639-1en-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Cerrahi Tıp Bilimleri Bölümü / Department of Surgical Sciences
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

106
checked on Dec 23, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.